Mushtaq, M. U., DiPersio, J. F., Azzi, J., Cooper, B. W., Koehne, G., Koura, D., Maakaron, J., Magenau, J., McClune, B., Rimando, J. C., Shah, N. N., Suh, H. C., Beuka, K., Sturrock, J., Nikam, M., Berglund, E., Hu, J., Keschner, Y., Etchin, J., Lydeard, J. R., Vasquez, M., O’Donnell, D., Mundelboim, G., Thosar, S., Canesin, G., Xavier-Ferrucio, J., Hyzy, S. L., Lloyd, D. M., Spink, K., Hummel, D., Lee-Sundlov, M. M., Scherer, J., Lin, M. I., Whangbo, J. S., Muffly, L. S. (2026). A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. Blood. https://doi.org/10.1182/blood.2025031053